ArticleAnnals of neurology2024

Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo-Controlled, Double-Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer Disease.

Joshua D Grill et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.